CRG

Zing Health is a tech-driven insurance company focused on enhancing Medicare Advantage for individuals aged 65 and above. It emphasizes community-based care, acknowledging the impact of social determinants on health outcomes. Zing Health aims to prioritize members' needs by offering personalized plans, access to specialized facilities, and dedicated care teams.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Calyxo is a medical device company established in 2016, dedicated to enhancing care for patients with kidney stones. The company specializes in developing innovative solutions to address this common and painful condition, which places significant demands on healthcare resources. Led by experienced executives and investors with a proven track record in urology, Calyxo's team is committed to making a difference in kidney stone treatment. Their flagship product is a vacuum-assisted retrieval device designed to efficiently remove multiple kidney stone fragments in a single insertion, providing an effective and intuitive procedure for doctors.

Founded in 2018, NavaDerm Partners operates dermatology centers across New York and New Jersey. It provides comprehensive dermatological services, including medical, surgical, and cosmetic procedures, with a focus on delivering world-class patient care through its team of over 40 board-certified dermatologists.

Founded in 2014, Treace Medical Concepts specializes in designing, manufacturing, and marketing innovative medical devices for foot and ankle physicians. Its flagship product is the ProHarvester, a minimally-invasive autograft extraction system. The company aims to improve patient outcomes while reducing healthcare costs.

Aerin Medical is a health technology company that develops non-invasive therapeutic devices to improve nasal breathing. Its portfolio includes VivAer for nasal airway obstruction and RhinAer for chronic rhinitis, along with VivAer Stylus and RhinAer Stylus, plus a compact console that delivers temperature-controlled radiofrequency energy to remodel nasal soft tissue. The technology targets the underlying causes of nasal congestion and offers alternatives to invasive surgery. The company, founded in 2011, is based in Sunnyvale, California.

Harmony Biosciences Holdings is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. It develops and commercializes therapies for rare neurological disorders with unmet medical needs. Its lead product is WAKIX (pitolisant), used to treat narcolepsy, and the company maintains a pipeline that includes candidates such as HBS-102, BP1.15205, ZYN002, EPX-100 and EPX-200.

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. Additionally, EyePoint is advancing its pipeline with innovative therapies such as EYP-1901, targeting wet age-related macular degeneration and diabetic retinopathy, and YUTIQ50 for uveitis. The company employs its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems that provide controlled drug delivery over extended periods. EyePoint has established strategic collaborations with various organizations to enhance its product offerings and has a commercial alliance for the joint promotion of DEXYCU. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was formerly known as pSivida Corp. and rebranded in March 2018.

Mid-Atlantic Dental Partners is a regional dental support organization (DSO) dedicated to enhancing the delivery of dental care through a collaborative approach involving patients, dentists, and support services. The organization provides a range of non-clinical services, including billing, collections, scheduling, practice marketing, financial management, clinical training, and dental staff recruitment. By managing these essential activities, Mid-Atlantic Dental Partners allows dental professionals to concentrate on patient care while maintaining clinical autonomy. The company is committed to improving the operational efficiency of dental practices and enhancing the work-life balance of its dental partners and their staff.

HNI Healthcare is a technology-driven physician practice management company specializing in delivering comprehensive facility-based physician programs. By combining its physicians' expertise with advanced processes and technologies, HNI Healthcare helps healthcare facilities enhance key quality metrics through a more integrated care model.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Fast Pace Health provides primary and urgent care to the communities they serve. They provide treatments for minor injuries, skin conditions, and diagnostics. Their services include behavioral health, dermatology care, occupational health, physical therapy, orthopedic care, and telehealth services.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

Synergy Pharmaceuticals Inc., located in New York, NY, with laboratories in Doylestown, PA, is a biopharmaceutical company dedicated to the research and development of innovative therapies for gastrointestinal disorders. The company focuses on treating conditions such as chronic idiopathic constipation and irritable bowel syndrome with constipation, leveraging proprietary analogs of the human gastrointestinal hormone uroguanylin. Its lead product, plecanatide, is a once-daily tablet designed to alleviate symptoms associated with these chronic conditions. Additionally, Synergy is developing dolcanatide, aimed at addressing inflammatory bowel disease by enhancing the digestive process. The company's approach involves the use of a novel class of guanylate cyclase-C agonists to target difficult-to-treat gastrointestinal diseases.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that specializes in innovative solutions for treating carotid artery disease. Founded in 2007, the company has developed a unique approach known as transcarotid artery revascularization (TCAR), which aims to reduce the risk of stroke and enhance patient safety during procedures. Silk Road Medical's product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which allows for direct access to the common carotid artery while temporarily reversing blood flow to protect the brain. Additionally, the ENROUTE Transcarotid Stent System and the ENHANCE Transcarotid Peripheral Access Kit support the TCAR procedure by facilitating safe and effective treatment. Through its minimally invasive techniques, Silk Road Medical seeks to establish TCAR as the standard of care for carotid artery disease, demonstrating improved clinical outcomes and reduced complications associated with traditional methods.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

EarLens is a privately held medical technology company focused on enhancing the hearing experience for individuals with hearing loss. The firm has pioneered the Earlens Contact Hearing Solution, a groundbreaking device that directly activates the natural hearing process. This innovative system utilizes low-frequency radio signals and a small lens placed on the eardrum to vibrate it, allowing for superior sound quality and a broader bandwidth than traditional hearing aids. Unlike conventional devices that amplify sound, the Earlens solution delivers sound directly to the eardrum, thereby minimizing feedback and ensuring clear hearing in various environments. The second generation of this technology received FDA clearance in 2019, marking a significant advancement in the standard of care for hearing performance.

EarLens is a privately held medical technology company focused on enhancing the hearing experience for individuals with hearing loss. The firm has pioneered the Earlens Contact Hearing Solution, a groundbreaking device that directly activates the natural hearing process. This innovative system utilizes low-frequency radio signals and a small lens placed on the eardrum to vibrate it, allowing for superior sound quality and a broader bandwidth than traditional hearing aids. Unlike conventional devices that amplify sound, the Earlens solution delivers sound directly to the eardrum, thereby minimizing feedback and ensuring clear hearing in various environments. The second generation of this technology received FDA clearance in 2019, marking a significant advancement in the standard of care for hearing performance.

Viveve Medical, Inc., established in 2005, specializes in designing, developing, manufacturing, and marketing medical devices for non-invasive treatment of women's health issues. Its primary product, the Viveve System, employs radiofrequency technology to address vaginal laxity, improve sexual function, and treat stress urinary incontinence. The company's products are sold through its own sales team and distributors in various regions worldwide, including the US, Europe, Asia Pacific, and Latin America. Viveve Medical is headquartered in Englewood, Colorado.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company headquartered in Raleigh, North Carolina, dedicated to addressing the needs of patients with chronic pain and opioid dependence. Founded in 1997, the company focuses on the development and commercialization of innovative pharmaceutical products, leveraging its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology. This technology allows for the creation of small erodible polymer films designed for effective application to the buccal mucosa. BioDelivery Sciences offers a range of products, including BELBUCA, a buprenorphine buccal film for chronic pain management, and BUNAVAIL, a buprenorphine and naloxone buccal film aimed at treating opioid dependence. Additionally, it provides ONSOLIS, a fentanyl buccal soluble film for managing breakthrough pain in cancer patients, and Symproic, which treats opioid-induced constipation in adults with chronic pain. The company's focus on novel drug delivery methods enables it to address important unmet medical needs in pain management and addiction medicine.

Endoceutics is a biopharmaceutical company focused on women's health, particularly in the areas of hormone-sensitive cancer prevention and treatment. The company specializes in the development of hormone therapies aimed at addressing breast cancer and endocrine-related disorders. Endoceutics is dedicated to advancing basic sciences, clinical research, and the commercialization of its products, which are designed to enhance the quality of life for women facing menopausal issues. With a diverse portfolio of products at various stages of development, Endoceutics aims to provide effective, physiological, and non-negative treatment options that address the specific health needs of women.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Hicuity Health is a technology-enabled clinical services provider specializing in high-acuity telehealth. It contracts to deliver care to more than 115 hospitals across 30 states on a 24/7/365 basis. The company combines remote patient monitoring, virtual care services, real-time clinical data integration, and access to specialized medical teams to support critical care delivery. It operates dedicated tele-care delivery centers and employs U.S. board-certified intensivists to support hospitals, families, and patients with improved oversight and care coordination, enabling scalable, around-the-clock critical care support for health systems.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Omeros discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, immunologic disorders, cancers, and addictive/compulsive disorders.

Access TeleCare is a provider of acute care telemedicine services designed for hospitals, health systems, post-acute providers, and physician networks. The company specializes in a range of telehealth services, including telecardiology, teleneurology, telepsychiatry, telepulmonology, telehospitalists, teleinfectious disease, and telematernal fetal medicine. By leveraging advanced technology, Access TeleCare facilitates virtual patient care, allowing healthcare organizations to develop and sustain telemedicine programs across various clinical specialties. The company's model supports healthcare providers in enhancing patient access to specialized care while maintaining quality and efficiency in service delivery.

US WorldMeds is a specialty pharmaceutical company based in Kentucky, focused on developing, licensing, and commercializing unique pharmaceuticals that address unmet medical needs. Founded in 2001 by CEO Paul Breckinridge "Breck" Jones, the company aims to create innovative treatments primarily for conditions such as Parkinson's disease, cervical dystonia, malignant hyperthermia, and other rare diseases. By leveraging local talent and expertise, US WorldMeds aspires to be a significant player in the pharmaceutical industry while maintaining its closely-held structure. The company is dedicated to improving the lives of patients and is committed to expanding its presence as a responsible corporate citizen, fostering innovation, and creating high-quality jobs in its headquarters in Louisville and its satellite offices and manufacturing facilities.

Iroko Pharmaceuticals, LLC is a specialty pharmaceutical company focused on developing and commercializing innovative products for pain management. Founded in 2007 and based in Philadelphia, Pennsylvania, the company offers a range of pharmaceutical products, including Indocid, Aldomet, TIVORBEX, ZORVOLEX, and VIVLODEX, which are primarily nonsteroidal anti-inflammatory drugs (NSAIDs) designed to address various types of pain, including osteoarthritis and acute pain in adults. Iroko leverages proprietary technology to create nano-formulated lower-dose NSAIDs, aiming to provide more effective and responsible pain relief options. The company has established a distribution and sales network that spans over 40 countries, emphasizing its commitment to extending the reach and benefits of its products in global markets.

Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. Its product offerings include the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for treating pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system suitable for various surgical approaches. The company serves a diverse customer base across the United States, Canada, Belgium, France, and Germany. Founded in 2004, Benvenue Medical is headquartered in Santa Clara, California, and is focused on developing innovative surgical solutions that enhance patient outcomes and restore spinal alignment.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that specializes in innovative solutions for treating carotid artery disease. Founded in 2007, the company has developed a unique approach known as transcarotid artery revascularization (TCAR), which aims to reduce the risk of stroke and enhance patient safety during procedures. Silk Road Medical's product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which allows for direct access to the common carotid artery while temporarily reversing blood flow to protect the brain. Additionally, the ENROUTE Transcarotid Stent System and the ENHANCE Transcarotid Peripheral Access Kit support the TCAR procedure by facilitating safe and effective treatment. Through its minimally invasive techniques, Silk Road Medical seeks to establish TCAR as the standard of care for carotid artery disease, demonstrating improved clinical outcomes and reduced complications associated with traditional methods.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Avinger, Inc. is a medical device company based in Redwood City, California, that specializes in developing catheter-based technologies for the treatment of peripheral arterial disease (PAD). Founded in 2007, Avinger designs, manufactures, and sells image-guided systems, including the Lightbox imaging console and the Ocelot family of catheters, which enable physicians to navigate and treat total blockages in arteries, known as chronic total occlusions (CTOs). The company's Pantheris device provides image-guided atherectomy, allowing for precise removal of arterial plaque in patients with PAD. Avinger's products are marketed to interventional cardiologists, vascular surgeons, and interventional radiologists, addressing significant needs in vascular health management.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates through two main segments: Diagnostic Substances and Therapeutic Development Programs. Central to its efforts is the Manocept platform, which targets the CD206 mannose receptor found on activated macrophages, enabling innovative approaches to diagnostic imaging and therapeutic delivery. This platform supports a variety of diagnostic modalities, including PET imaging, and is designed to address immune and inflammation-related diseases. Notably, Navidea offers NAV4694, a PET imaging agent for assessing Alzheimer’s disease and mild cognitive impairment. Additionally, the company is advancing other diagnostic substances and therapeutic programs, with a collaboration agreement in place with IMV Inc. to explore combined immunotherapeutic effects. Founded in 1983 and headquartered in Dublin, Ohio, Navidea Biopharmaceuticals previously operated under the name Neoprobe Corporation until 2012.

Ceterix Orthopaedics, Inc. is a medical technology company that specializes in developing innovative surgical tools for arthroscopic procedures. Founded in October 2010 and based in Fremont, California, Ceterix offers the NovoStitch® Plus Meniscal Repair System, designed to address complex meniscal tears, including horizontal, radial, and root tears. The company also provides the Novocut Suture Manager, a device that facilitates efficient suture management. Ceterix's technology enables orthopedic surgeons to create intricate suture patterns in tight joint compartments while safeguarding surrounding structures, such as nerves and cartilage. This advancement allows for improved outcomes in arthroscopic procedures across various joints, including the knees, hips, and shoulders. Ceterix was previously known as SuturePro Technologies, Inc. before rebranding in April 2011 and is currently a subsidiary of Smith & Nephew plc.

TearLab Corporation is an in-vitro diagnostic company based in Escondido, California, specializing in the development and marketing of innovative tear testing technologies for the diagnosis of dry eye disease. The company’s flagship product, the TearLab Osmolarity System, is a proprietary platform that allows eye care practitioners to measure tear film osmolarity and identify sensitive biomarkers using only nanoliters of tear film at the point-of-care. This system includes a disposable microfluidic chip, a hand-held device known as the TearLab Pen for sample collection, and the TearLab Reader, a desktop unit that provides quantitative results. Founded in 1996, TearLab aims to enhance the standard of care in ophthalmology through objective and precise testing methodologies.

Imaging Advantage is a prominent provider of advanced, evidence-based radiology solutions designed to enhance the efficiency and utilization of healthcare services across the United States. The company offers innovative, scalable cloud-based technology that integrates various information technology systems and employs clinical algorithms to align healthcare supply and demand. Imaging Advantage serves major healthcare systems in states including Arizona, California, Illinois, Michigan, Ohio, Oregon, and Texas, as well as in other significant metropolitan areas nationwide. By focusing on optimizing provider utilization, the company aims to improve the overall effectiveness of radiology services within the healthcare sector.

Imaging Advantage is a prominent provider of advanced, evidence-based radiology solutions designed to enhance the efficiency and utilization of healthcare services across the United States. The company offers innovative, scalable cloud-based technology that integrates various information technology systems and employs clinical algorithms to align healthcare supply and demand. Imaging Advantage serves major healthcare systems in states including Arizona, California, Illinois, Michigan, Ohio, Oregon, and Texas, as well as in other significant metropolitan areas nationwide. By focusing on optimizing provider utilization, the company aims to improve the overall effectiveness of radiology services within the healthcare sector.

Blue Belt Technologies, Inc. specializes in developing and commercializing robotics-assisted technologies for orthopedic surgery and other medical specialties. The company is known for its Navio surgical system, which combines handheld intelligent instruments with a CT-free registration and patient-specific planning process, enhancing the precision of surgical procedures. Additionally, Blue Belt offers the STRIDE unicondylar knee system, designed to address early-stage osteoarthritis in the knee. Their software applications assist surgeons in creating tailored implant plans for unicondylar and patellofemoral knee replacements, ensuring proper localization of components and soft-tissue balance. Beyond its technological offerings, Blue Belt provides support services, marketing resources, maintenance programs, and onsite training for healthcare professionals. Founded in 2003 and headquartered in Plymouth, Minnesota, Blue Belt Technologies became a subsidiary of Smith & Nephew in 2016.

Astute Medical, Inc. is a life science tools company focused on improving the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers. Founded in 2007 and based in San Diego, California, with an additional location in Paris, France, the company specializes in creating novel diagnostic tests that enable rapid diagnosis and risk assessment for conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Astute Medical's flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers associated with acute kidney injury, while the Astute140 meter converts the test's fluorescent signal into a single numerical result. The company markets its products primarily in the United States and Europe and operates as a subsidiary of bioMérieux S.A.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

AFT Pharmaceuticals is a New Zealand-based company that develops, licenses, and sells pharmaceutical products for prescription and consumer use. It operates in New Zealand, Australia, Southeast Asia, and other international markets, offering products for allergy, eye care, first aid, fungal infections, pain management, skin care, and supplements, and it also distributes pharmaceuticals. The company focuses on intellectual property development and owns a portfolio of products including Maxigesic, Capsaicin creams, Crystaderm, Kiwisoothe, and Micolette. Founded in 1997 and headquartered in Auckland, it serves multiple regions through geographically organized operations and licensing and distribution activities aimed at expanding access to healthcare products.

NanoString Technologies provides life science tools for translational research and molecular diagnostics. It offers the nCounter Analysis System, featuring automated liquid handling and digital detection, along with customizable assays and software for data analysis. The company also develops spatial genomics systems like GeoMx DSP and Hyb & Seq. Its products enable various applications in basic research, translational medicine, and diagnostics.

Biodesix, Inc. is a diagnostic solutions company based in Boulder, Colorado, specializing in blood-based tests for lung cancer and related services. The company offers a range of diagnostic tests, including the Nodify XL2 and Nodify CDT tests, which assist physicians in assessing the risk of malignancy in patients with suspicious lung nodules. Additionally, Biodesix provides tumor profiling and immune profiling tests, such as GeneStrat and VeriStrat, to support timely treatment decisions for oncologists. These tests are processed in a CLIA-certified laboratory, with results typically available within 72 hours. Beyond its diagnostic offerings, Biodesix also engages in clinical research, development, and testing services for biopharmaceutical companies, focusing on the development and commercialization of companion diagnostics to enhance therapeutic efficacy. Established in 2005, Biodesix continues to advance its proprietary mass spectrometry-based discovery platform to improve patient outcomes in lung disease.

Solta Medical, Inc. is a medical device company specializing in energy-based systems for aesthetic applications. Founded in 1995 and headquartered in Hayward, California, the company designs, develops, and manufactures a range of products for skin rejuvenation and body contouring. Notable offerings include the Thermage NXT system, which provides non-invasive skin tightening and cellulite enhancement, as well as the Fraxel re:fine, re:store, and re:pair systems, which address various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. These systems comprise handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and gynecologists, and distributes its products through a direct sales force and a network of distributors both in the United States and internationally. The company was previously known as Thermage, Inc. before rebranding to Solta Medical in January 2009.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

RainDance Technologies, Inc. specializes in developing advanced genomic tools for non-invasive liquid biopsy applications, focusing on cancer detection, treatment, and the study of inherited and infectious diseases. The company's flagship product, the RainDrop digital polymerase chain reaction platform, utilizes picoliter-sized droplets to facilitate multiplex detection of genetic material, including DNA and RNA. Additionally, RainDance offers the RainDrop Plus digital PCR system, which integrates next-generation sequencing (NGS) amplicon enrichment with digital PCR capabilities. Their automated ThunderStorm solution enhances NGS content enrichment, allowing laboratories to process multiple samples efficiently while ensuring high-quality data. The ThunderBolts panels target critical cancer mutations and specific genetic markers associated with myeloid disorders. RainDance's products include a range of consumables designed to optimize various laboratory processes. Founded in 2004 and headquartered in Billerica, Massachusetts, the company serves research institutions and laboratories globally through a network of sales representatives and distributors. RainDance Technologies operates as a subsidiary of Bio-Rad Laboratories, Inc.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

Tandem Diabetes Care is a medical device company that designs, manufactures, and markets insulin pumps and related diabetes management solutions. Founded in 2006 and headquartered in San Diego, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a compact pump, a 300‑unit disposable cartridge, and an infusion set. The system is available with Basal‑IQ, Control‑IQ, and G5 integration features, and can be updated through the Tandem Device Updater. Tandem also offers the t:connect web application for data visualization and the Sugarmate mobile app for insulin‑using patients. In development are the t:sport pump, the Mobi and Tobi tubeless pumps, and the Sigi patch pump. The company partners with Dexcom for integrated glucose monitoring and sells its products primarily in the United States, with a growing presence in other developed markets.

Corium International specializes in the development, manufacture, and commercialization of transdermal and transmucosal drug delivery systems for various therapeutic areas. Its product portfolio includes treatments for hypertension, chronic pain, teeth whitening, osteoporosis, Alzheimer's disease, psychiatric disorders, Parkinson's disease, and motion sickness. The company focuses on enhancing therapeutic profiles and improving patient outcomes through its proprietary technologies.

Bioniche Pharma Group manufactures and markets sterile injectable pharmaceutical products.